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Abstract. 
 
We have used microinjection and time-lapse 
video microscopy to study the role of cyclin A in mito-
 
sis. We have injected puriﬁed, active cyclin A/cyclin-
 
dependent kinase 2 (CDK2) into synchronized cells 
at speciﬁc points in the cell cycle and assayed its effect 
on cell division. We ﬁnd that cyclin A/CDK2 will drive 
G2 phase cells into mitosis within 30 min of microinjec-
tion, up to 4 h before control cells enter mitosis. Often 
this premature mitosis is abnormal; the chromosomes 
do not completely condense and daughter cells fuse. 
Remarkably, microinjecting cyclin A/CDK2 into S 
phase cells has no effect on progress through the fol-
lowing G2 phase or mitosis. In complementary experi-
ments we have microinjected the amino terminus of 
 
p21
 
Cip1/Waf1/Sdi1
 
 (p21N) into cells to inhibit cyclin
A/CDK2 activity. We ﬁnd that p21N will prevent S 
phase or G2 phase cells from entering mitosis, and will 
cause early prophase cells to return to interphase. 
These results suggest that cyclin A/CDK2 is a rate-lim-
iting component required for entry into mitosis, and for 
progress through mitosis until late prophase. They also 
suggest that cyclin A/CDK2 may be the target of the re-
cently described prophase checkpoint.
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P
 
ROGRESS
 
 through the cell cycle is regulated by se-
quential waves of different cyclin/cyclin-dependent
 
kinase (CDK)
 
1
 
 activities. In animal cells, cyclin
E/CDK2 is required for the initiation of DNA replication,
and cyclin B/CDK1 for the entry into mitosis. Cyclin A is
unusual in that it appears to be required for both DNA
synthesis and for mitosis (Pagano et al., 1992). With re-
spect to its S phase role, cyclin A may be rate limiting for
DNA replication because it can accelerate the entry of G1
phase cells into S phase when overexpressed from a tetra-
cycline-inducible promoter (Resnitzky et al., 1995). More-
over, cyclin A will promote DNA replication in 
 
Xenopus
 
egg (Strausfeld et al., 1996) and human cell extracts
(D’Urso et al., 1990; Fotedar et al., 1996a; Krude et al.,
1997), and has been localized to sites of DNA replication
(Cardoso et al., 1993; Sobczak et al., 1993). Conversely,
microinjecting anti–cyclin A antibodies, or antisense RNA,
will prevent mammalian tissue culture cells from replicat-
ing their DNA (Girard et al., 1991; Zindy et al., 1992). Al-
though cyclin A does appear to be necessary for S phase,
there is some debate over whether cyclin A is needed to
initiate DNA replication, or whether it plays a role in con-
tinuing DNA synthesis, perhaps to prevent rereplication
(Petersen et al., 1999).
The role of cyclin A at mitosis is also ill defined. The
most definitive evidence that cyclin A is required for cells
to begin mitosis is the observation that in a 
 
Drosophila
 
mutant that lacks cyclin A, cells arrest in G2 phase after
the supply of maternal cyclin A is exhausted (Knoblich
and Lehner, 1993; Lehner and O’Farrell, 1989). In support
of this, anti–cyclin A antibodies arrest cells before mitosis
when injected into tissue culture cells in G2 phase (Pagano
et al., 1992). Moreover, cyclin A mRNA alone can induce
meiotic maturation when injected into 
 
Xenopus
 
 oocytes
(Swenson et al., 1986). In this assay, and also in genetic
analyses using 
 
Drosophila 
 
mutants that lack cyclin A or
cyclin B, or both, it appears that cyclin A acts synergisti-
cally with cyclin B to induce mitosis (Devault et al., 1992;
Knoblich and Lehner, 1993). However, these experiments
did not reveal a specific role for cyclin A compared with
cyclin B in mitosis. One difference that has been observed
is that amino-terminal truncated mutants of clam cyclin B,
but not cyclin A, activate ubiquitin-mediated cyclin de-
struction in vitro
 
 
 
(Luca et al., 1991).
The initiation of mitosis is subject to a number of impor-
tant checkpoint controls to ensure that DNA is completely
replicated and undamaged before cell division begins (re-
viewed in Elledge, 1996). Both unreplicated and damaged
DNA are able to prevent mitosis by inhibiting the dephos-
phorylation and consequent activation of cyclin B/CDK1.
Recent results have emphasized the importance of the
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Cds1 and Chk1 protein kinases that are activated by the
presence of unreplicated DNA and/or damaged DNA
(Fogarty et al., 1997; Furnari et al., 1997; Peng et al., 1997;
Sanchez et al., 1997; Boddy et al., 1998; Lindsay et al.,
1998). Once activated, Chk1 and Cds1 phosphorylate and
inactivate cell division cycle (Cdc)25C, in part by creating
phosphorylation-dependent binding sites for 14-3-3 pro-
teins that may sequester Cdc25C (Lopez-Girona et al.,
1999). The end result is to prevent Cdc25 from dephos-
phorylating and activating cyclin B/CDK1, and, therefore,
prevent the cell from entering mitosis. In addition to
this pathway, there may be a role for the CDK inhibitor
p21
 
Cip1/Waf1/Sic1
 
 in preventing mitosis in the presence of
DNA damage. p21
 
Cip1/Waf1/Sic1
 
 is able to bind and inhibit di-
rectly a number of different cyclin/CDKs, including cyclin
E/CDK2 and cyclin A/CDK2, but not cyclin B/CDK1 to a
significant extent (Harper et al., 1995). The carboxyl ter-
minus of p21
 
Cip1/Waf1/Sic1
 
 is also able to bind to PCNA
(Chen et al., 1995; Goubin and Ducommun, 1995; Naka-
nishi et al., 1995; Warbrick et al., 1995), and this ap-
pears to contribute to a DNA damage checkpoint when
p21
 
Cip1/Waf1/Sic1
 
 is overexpressed (Tournier et al., 1996; Cay-
rol et al., 1998). Once cells have entered mitosis, there is
another checkpoint in early prophase that will cause a cell
to return to an interphase-like state when the chromo-
somes are damaged (Rieder and Cole, 1998), although the
nature of the regulator(s) involved has not been defined.
In this paper, we demonstrate that cyclin A/CDK2 activ-
ity is a rate-limiting component for entry into mitosis be-
cause exogenous active cyclin A/CDK2 will drive cells pre-
maturely into mitosis, effectively eliminating G2 phase.
However, cyclin A/CDK2 cannot overcome the unrep-
licated DNA checkpoint. We further show that cyclin
A/CDK activity is required for cells to complete prophase,
because inhibiting cyclin A/CDK activity in mid prophase
causes cells to return to G2 phase. Cyclin A/CDK becomes
dispensable in late prophase at the same time that cyclin
B1 translocates into the nucleus. This suggests that the
prophase checkpoint may act by inhibiting cyclin A/CDK.
 
Materials and Methods
 
Cell Culture and Synchronization
 
HeLa cells were cultured in DME and synchronized in G2 phase by a thy-
midine-aphidicolin block (Pines and Hunter, 1989). PtK1 cells (European
Collection of Cell Cultures no. 91013163) were cultured in Ham’s F-12
medium (GIBCO BRL), 100 U/ml penicillin-G, 0.1 mg/ml streptomycin,
1 mM Na pyruvate, 10% foetal bovine serum, and 1% (vol/vol) Fungizone
(GIBCO BRL) at 37
 
8
 
C/6% CO
 
2
 
.
 
Construction and Purification of GST-p21N
 
Human p21
 
Cip1
 
 (1–90) was generated by PCR from the p21
 
Cip1
 
 cDNA
(kind gift of Dr. J. Roberts, Fred Hutchison Cancer Center
 
, 
 
Seattle, WA)
using the following primers; 5
 
9
 
 GCCGGATCCCCATGTCAGAACCG,
and 3
 
9
 
 GCCGGATCCCTATCCCAACTCATCCCGGCCTCG. After di-
gestion with BamHI, the PCR product was subcloned into the BamHI site
of pGEX3T (Pharmacia) to yield pGEX-p21N. For expression, pGEX-
p21N was used to transform 
 
E
 
.
 
 coli 
 
(BL21) and the GST-p21N fusion pro-
tein was purified by glutathione Sepharose chromatography after which it
was 
 
.
 
90% pure on a Coomassie blue R250–stained SDS–polyacrylamide
gel. The concentration of purified GST-p21N was determined by Coo-
massie blue R250 staining using BSA standards. All constructs were con-
firmed by sequencing on an automatic sequencer (Department of Bio-
chemistry, University of Cambridge).
 
Cyclin-Cdk Expression, Purification, and Injection
 
Cyclin A/CDK2, cyclin E-CDK2, and cyclin A/CDK2
 
K33R
 
 were expressed
in and purified from baculovirus-infected Sf9 cells as previously described
(Krude et al., 1997), as were cyclin B1-MmGFP and cyclin B1 (Clute and
Pines, 1999). Proteins were 
 
.
 
90% pure on silver-stained gels. Proteins
were concentrated in injection buffer (200 mM NaCl, 12.5 mM Tris-Cl, pH
8.0, 2.5 mM DTT, 1 mM EDTA, and 1 mM glutathione) in a Vivaspin
5,000 MW cut-off microconcentrator (Vivascience) and 
 
z
 
5% of the cell
volume injected into cells using an Eppendorf semiautomatic microinjec-
tor (Eppendorf) attached to a Leica DMIRBE microscope (Leica). The
cDNAs for Cdc25B and Cdc25C, mutant and wild-type (kind gifts of Dr. I.
Hoffmann, DKFZ, Germany) were cloned into pCMX under the CMV
promoter, and injected into cells as described (Hagting et al., 1998).
 
Histone H1 Kinase Assays
 
Histone H1 kinase assays with purified cyclin A/CDK2 or cyclin B1-cdc2
were performed as described (Krude et al., 1997). The amount of 
 
33
 
P in-
corporated into histone H1 was quantified using a scintillation counter
(Beckman).
 
Immunofluorescence
 
Cells were fixed in 50:50 vol/vol methanol/acetone and stained with affin-
ity-purified anti–cyclin B1 serum at 1:200 dilution, and with an anti–
 
b
 
 tu-
bulin monoclonal antibody (Amersham) at 1:100 as described (Pines,
1997). As secondary antibodies, Cy5-labeled anti–rabbit and Cy2-labeled
anti–mouse antibody were used at 1:200 and 1:500, respectively.
 
Time-Lapse Imaging and Analysis
 
Cells were plated and synchronized in 
 
D
 
T 0.15-mm dishes (Bioptechs).
For microinjection and observation, the culture medium was replaced
with CO
 
2
 
-independent medium without phenol red (GIBCO BRL) and
overlaid with mineral oil. Dishes were maintained at 37
 
8
 
C using the 
 
D
 
T
system (Bioptechs). Lambda 10-2 filter wheels (Sutter Instruments) with
custom filters (Chroma Technology) were used to control the excitation
and emission wavelengths (for cyclin B1-GFP imaging). The filter wheel
on the camera port also had a polaroid filter to capture DIC images. Im-
ages were captured on a Leica DMIRBE with a PentaMax camera (Prince-
ton Instruments), and a PowerWave computer (PowerComputing) or
Macintosh 8600 (Apple) computer running IP Lab Spectrum imaging soft-
ware (Scanalytics Inc.) as described (Karlsson and Pines, 1998). To quan-
tify the amount of fluorescence in a cell over time, a region encompassing
the cell was drawn manually and copied onto successive fluorescence im-
ages of a time series saved in IP Lab Spectrum format. The sum of pixel
intensities (total fluorescence) and the number of pixels (area) of this re-
gion in successive images was quantified using IP Lab Spectrum. The
mean pixel intensity outside the region of cell fluorescence (mean back-
ground) was measured and multiplied by the number of pixels (area) of
the original cell region. This represented that amount of the total fluores-
cence in the cell region which was due to background rather than GFP flu-
orescence. This was subtracted from the total fluorescence of the cell to
give a figure representing the total amount of GFP fluorescence, and thus,
the amount of GFP-linked protein in the cell (total fluorescence minus
background). Captured images were animated with Adobe Premiere and
the time to reach mitosis recorded for each cell. Cells were scored as en-
tering mitosis when they had rounded up and condensed their chromo-
somes. Time-lapse imaging showed that cells were still viable after prema-
ture mitosis because cells exited mitosis and flattened out. Images were
exported to Adobe Photoshop for printing.
 
Results
 
To investigate the role of cyclin A in mitosis, we have used
a time-lapse microscopy assay to determine the effect
on entry into mitosis of inhibiting or enhancing cyclin
A/CDK2 kinase activity. In this assay, cells were first syn-
chronized in S or G2 phase by a thymidine-aphidicolin
block and release regime,
 
 
 
and then viewed by time-lapse
DIC microscopy to assess when they entered, and subse-
quently exited, mitosis. In each experiment, control cells 
Furuno et al. 
 
Cyclin A Is Required for Prophase
 
297
 
were simultaneously visualized in the same field as the ex-
perimental cells. Cells were demonstrated to be in S or G2
phase by flow cytometry and by the incorporation of
BrdU.
 
Cyclin A/CDK2 Causes G2 Phase but Not S Phase 
Cells to Enter Mitosis Prematurely
 
To increase the amount of active cyclin A/CDK2 in a
specific phase of the cell cycle we microinjected cyclin
A/CDK2 purified from baculovirus-infected Sf9 cells into
synchronized HeLa cells. This complex was an active his-
tone H1 kinase and 
 
.
 
90% pure on a silver-stained SDS-
PAGE gel, as previously described (Krude et al., 1997).
We found that injecting a final concentration of 2–4 
 
m
 
M
cyclin A/CDK2, which represents 
 
z
 
20–40-fold excess over
the endogenous cyclin A, into early G2 cells (
 
z
 
7 h after
release from an aphidicolin block), caused the cells to be-
gin to enter mitosis 30 min to 1 h after injection (Fig. 1 A).
This was at least 4 h before control. Uninjected cells began
mitosis. This effect required CDK2 kinase activity, be-
cause cyclin A, in a complex with an inactive CDK2
 
K33R
 
mutant, did not promote, indeed it slightly inhibited, entry
into mitosis (Fig. 1 A). The effect was specific to cyclin
A/CDK2 because microinjecting the same amount of cy-
clin E-CDK2 did not cause G2 phase cells prematurely to
enter mitosis (Fig. 1 A). (We injected an equal amount of
cyclin E/CDK2 rather than attempt to inject an equal
amount of kinase activity, because no single substrate can
be used to compare the physiological specific activities of
different cyclin/CDKs. This is due to the substrate-target-
ing role of the cyclin which causes the apparent activity of
a cyclin/CDK to depend on the substrate in the assay. For
example, unlike cyclin A/CDK2, cyclin E/CDK2 only
weakly phosphorylates histone H1, but it strongly phos-
phorylates NPAT (Zhao et al., 1998).) The mitosis-pro-
moting activity of cyclin A/CDK2 was also dose depen-
dent, because injecting a final concentration of 0.4–0.8 
 
m
 
M
cyclin A/CDK2 (a four- to eightfold excess over endoge-
nous cyclin A/CDK2) caused early G2 phase cells to enter
mitosis earlier than control cells, but later than cells in-
jected with 2–4 
 
m
 
M cyclin A/CDK2 (Fig. 1 A). Overall,
these results suggested that cyclin A/CDK2 might be a
rate-limiting component in G2 phase for the initiation of
mitosis.
We then asked whether cyclin A was simply able to ac-
celerate cells through G2 phase, or whether it was also
able to cause mitosis in cells with unreplicated DNA.
Therefore, we injected cyclin A/CDK2 into S phase cells
(2 h after release from an aphidicolin block). This caused
 
,
 
10% of the cells to enter mitosis and, furthermore,
 
.
 
90% of the cells had an apparently normal length G2
phase, suggesting either that the exogenous cyclin A/CDK2
had been inactivated, or that the appropriate mitotic sub-
strates were not present in S phase (Fig. 1 B).
Although human cyclin A had been shown to accumu-
late through S and G2 phases until it was rapidly degraded
in mitosis (Pines and Hunter, 1990), it was possible that
the exogenous cyclin A was inactivated in S phase through
proteolysis. To test this, we injected a cyclin A–GFP fu-
sion protein which acts as a proper marker for cyclin A; it
binds and activates CDK2, localizes to the nucleus, and is
rapidly degraded in mitosis (del Elzen, N., and J. Pines,
manuscript in preparation). This fusion protein also has
mitosis promoting activity in G2 phase cells. We were able
to measure the rate of proteolysis of the protein by mea-
suring the amount of GFP fluorescence (Clute and Pines,
1999). There was a low rate of degradation in S and in G2
phases, which increased with larger amounts of protein,
but this rate was insufficient to account for the inactivation
of cyclin A. Furthermore, the rate was the same in S or G2
phase cells (Fig. 1 C). Given that cyclin A was equally sta-
ble whether injected into cells in S phase or G2 phase, this
suggested that S phase cells do not inactivate exogenous
cyclin A by proteolysis.
 
Cells that Enter Mitosis Prematurely Do Not
Properly Divide
 
Cells that are forced to enter mitosis without completing
DNA synthesis undergo premature chromosome conden-
sation/mitotic catastrophe and die after arresting in mito-
sis. However, this was not the case for the G2 cells that
were forced to enter mitosis prematurely by the injection
of cyclin A/CDK2. In many of these cells, mitosis was con-
siderably prolonged, from 
 
z
 
1 h to between 3 and 4 h.
Prophase and prometaphase/metaphase were the most
prolonged; anaphase and telophase were of relatively
normal duration. In cells injected in mid to late G2 phase
the chromosomes clearly condensed and aligned on the
metaphase plate, and these cells subsequently divided and
remained separate (Fig. 2 A). However, in cells injected in
early G2 phase, and in the small minority of S phase cells
that prematurely entered mitosis when we injected cyclin
A/CDK2, condensed chromosomes were never visible and
in these cases the sister cells fused soon after cytokinesis
(Fig. 2 B). This phenotype is, therefore, likely to reflect
premature condensation of incompletely replicated DNA.
 
The Effect of Cyclin A/CDK2 Can Be Blocked by 
Dominant Negative Mutants of Cdc25B and Cdc25C
 
We wished to determine whether the M phase–promoting
activity of cyclin A/CDK2 was acting through known regu-
lators of cyclin B1/CDK1. Therefore, we injected cells
with expression constructs that encoded inactive mutants
of Cdc25B or Cdc25C, which act as dominant negative mu-
tants and arrest cells in G2 phase. A dominant negative
mutant of Cdc25B was able to block the effect of injecting
cyclin A/CDK2 (Fig. 3), as did a dominant negative
Cdc25C, but to a lesser extent than the Cdc25B mutant
(data not shown). Cells injected with cyclin A/CDK2 plus
the dominant negative forms of Cdc25B or Cdc25C did
round up, and their chromosomes partially condensed, but
their nuclear envelopes remained intact and they did not
divide (data not shown). These results suggested that cy-
clin A/CDK2 was acting upstream of the activation of cy-
clin B/CDK1, and that cyclin B1/CDK1 activity was re-
quired for nuclear envelope breakdown but not for the
initial stages of chromosome condensation (see below).
 
Inhibiting Cyclin A/CDK2 Prevents Cells from
Entering Mitosis
 
Our results suggested that cyclin A was able to promote 
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Figure 1. (A) Cyclin A/CDK2
will promote mitosis in G2 phase
cells. HeLa cells were synchro-
nized at the beginning of S phase
by a thymidine-aphidicolin block
and then released. After 7 h cells
entered G2 phase and at least 35
cells were injected (time marked
by the arrow) with either cyclin
A/CDK2 (2–4 mM, filled dia-
monds; 0.4–0.8 mM, open dia-
monds), or cyclin E-CDK2 (2–4
mM, filled squares), or cyclin
A/CDK2K33R (open squares) or
uninjected (open circles). Cells
were followed by time-lapse DIC
microscopy to determine when
they entered mitosis as defined
by rounding up and chromosome
condensation. The results are
plotted with zero time set as the
time when 50% of the control
cells entered mitosis. The results
are representative of at least two
independent experiments. (B)
Cyclin A/CDK2 does not pro-
mote mitosis in S phase cells.
HeLa cells were synchronized at
the beginning of S phase by a thy-
midine-aphidicolin block and
then released. After 2 h cells
were either injected (time
marked by the arrow) with cyclin
A/CDK2 (2–4 mM; filled dia-
monds, n 5 36) or not (open cir-
cles) and followed by time-lapse
microscopy to determine when
they entered mitosis. The results
are plotted with zero time set as
the time when 50% of the control
cells entered mitosis. The results
are representative of at least
three independent experiments.
(C) Cyclin A/CDK2 is not inacti-
vated in S phase cells by proteol-
ysis. HeLa cells were synchro-
nized at the beginning of S phase
or G2 phase by a thymidine-
aphidicolin block and release re-
gime. S phase (squares) or G2
phase (diamonds) cells were
injected with purified cyclin
A-GFP and imaged by DIC and
epifluorescence microscopy every
3 min, keeping all parameters
(exposure time, magnification
and numerical aperture of the
lens) constant. The amount of
fluorescence in the cells was
quantified (see Materials and
Methods) and the rate of de-
crease calculated for S phase (114
pixels per minute) and G2 phase
(224 pixels per minute). The ef-
fect of bleaching was minimal as
most of the decrease was pre-
vented by adding a proteasome
inhibitor MG132 (not shown).
Values are representative of two
independent experiments. 
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mitosis once cells had replicated their DNA, and, there-
fore, we wished to determine the period in G2 phase for
which cyclin A was required to initiate mitosis. To answer
this question, we designed a means to inhibit cyclin
A/CDK2 activity at specific points in G2 and M phase.
To inhibit cyclin A/CDK2 kinase activity, we chose to
microinject the first 90 amino acids of human p21
 
Waf1/Cip1/Sdi1
 
(hereafter referred to as p21N) purified as a GST-fusion
protein from 
 
E
 
.
 
 coli
 
. This construct contained both a cyclin
binding motif (Cy1) and a CDK-inhibitory motif (Chen et al.,
1995, 1996; Goubin and Ducommun, 1995; Warbrick et al.,
1995; Fotedar et al., 1996b), and efficiently inhibited cyclin
A/CDK2 more than cyclin B/CDK1 in vitro
 
 
 
(Fig. 4 A).
The effect of injecting GST-p21N was specific to the p21N
moiety because injecting either buffer or GST had no
effect on the dynamics of entry into mitosis (Fig. 4 B).
Figure 2. Cells forced into premature mitosis by cyclin A often fail to condense fully their chromosomes. HeLa cells were synchronized
in G2 phase and injected with 2–4 mM cyclin A/CDK2 as in Fig. 1 A. Representative DIC images are shown of a cell that does (A) and
a cell that does not (B) fully condense its chromosomes at metaphase. The cell that does not condense its chromosomes divides but the
daughter cells fuse.
Figure 3. A catalytically inactive
mutant of Cdc25B prevents cyclin
A/CDK2 from promoting premature
mitosis. HeLa cells in S phase were mi-
croinjected or not with a catalytically
inactive form of cdc25B3 cDNA under
the CMV promoter at a concentration
of 0.1 mg/ml. When cells entered G2
phase (z4 h later) they were injected
or not with cyclin A/CDK2 to a final
concentration of z2–4  mM. A mini-
mum of 36 cells for each sample were
followed by time-lapse DIC micros-
copy as in Fig. 1 and the results are
plotted with zero time set as the time
when 50% of the control cells entered
mitosis. The results are representative
of at least two independent experi-
ments. 
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Figure 4.
 
p21N inhibits cyclin A/CDK2 and blocks cells in G2 phase. (A) p21N inhibits cyclin A/CDK2 better than cyclin B-cdc2 in
vitro. Cyclin A/CDK2 and cyclin B-cdc2 were produced and purified from baculovirus infected cells and assayed for histone H1 kinase 
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Furthermore, coinjection with an equal amount of cyclin
A/CDK2 negated the effect of p21N (Fig. 4 B). We did not
use full-length p21
 
Cip1/Waf1/Sic1
 
 because we found that this
activated a G2 checkpoint (data not shown) related to that
activated by overexpressing PCNA, as previously reported
(Tournier et al., 1996; Cayrol et al., 1998).
We found that injecting 
 
z
 
2 
 
m
 
M p21N, which represents
a 
 
z
 
40-fold excess over the endogenous cyclin A (data not
shown), at 10 h after release from an aphidicolin block
caused cells to arrest in G2 phase (Fig. 4 B). (We injected
excess p21N to ensure that we completely blocked cyclin
A/CDK2 activity.) Previous studies in which full-length
p21 was overexpressed have found that cyclin B1 accu-
mulated in the nucleus (Bates et al., 1998; Dulic et al.,
1998). Therefore, we stained cells blocked in G2 phase by
p21N with anti–cyclin B1 antibodies and found that cyclin
B1 remained cytoplasmic (Fig. 4 C). Thus, full-length
p21
 
Cip1/Waf1/Sic1
 
 does not cause cyclin B1 to accumulate in
the nucleus by inhibiting cyclin A/CDK kinase activity.
 
Cdc25s and Active Cyclin B/CDK1 Can Overcome the 
Block Imposed by p21N
 
Our previous results showed that dominant negative mu-
tants of Cdc25B and Cdc25C blocked the mitosis-promot-
ing activity of cyclin A/CDK2. Therefore, we assayed
whether overexpressing Cdc25B and C, or microinjecting
active cyclin B1/CDK1, could promote mitosis when cyclin
A/CDK2 was inhibited with p21N. Injecting the cDNAs
for Cdc25B (Fig. 5 A) or Cdc25C (Fig. 5 B), into cells
blocked in G2 phase by injection of p21N caused cells to
enter mitosis, although passage through mitosis was de-
layed (Fig. 5). We were also able to force cells into mitosis
with active cyclin B1/CDK1 purified from baculovirus-
infected Sf9 cells (Fig. 5 C). However, this differed from
the effect of cyclin A/CDK2 because the time to entry into
mitosis did not depend on the dose of the cyclin B1/CDK1
kinase, and the nuclear envelope broke down as soon as
the cells rounded up. Thus, it appeared that the function of
cyclin A/CDK2 to promote mitosis was bypassed by di-
rectly activating cyclin B1/CDK1, suggesting that cyclin
A/CDK2 acted upstream of cyclin B/CDK1. These results
also showed that p21N did not inhibit cyclin B/CDK1 in
vivo.
 
p21N Will Cause Prophase Cells to Return
to Interphase
 
To define the period of the cell cycle for which cyclin
 
A/CDK2 kinase was required for the initiation of mitosis,
we injected p21N into late G2 phase and mitotic cells. As ex-
pected, we found that late G2 phase cells remained in G2
phase. Prometaphase cells that had undergone nuclear en-
velope breakdown continued to progress through mitosis
(10/10 cells), and this was further evidence that p21N did
not block cyclin B1/CDK1. However, when we injected
p21N into prophase HeLa cells that had not yet reached
NEBD, these cells did not continue through mitosis but
decondensed their chromosomes, flattened out and ar-
rested, apparently in interphase again (6/6 cells, and see
below). Control prophase cells injected with GST com-
pleted mitosis (data not shown). After 2–3 h, cells injected
with p21N began to re-enter mitosis and this time com-
pleted cell division. This observation was reminiscent of
the prophase checkpoint that had recently been identified
by Rieder and Cole (1998), who found that PtK
 
1
 
 cells in
early prophase, 
 
.
 
30 min before NEBD, would return to
interphase after nuclear irradiation. Therefore, we micro-
injected p21N into prophase PtK
 
1
 
 cells. We found that
prophase PtK
 
1
 
 cells returned to interphase up to the time
when the nucleoli disappeared in mid prophase (17/17
cells Fig. 6 B). p21N could not prevent cells later in
prophase from progressing through mitosis; these cells un-
derwent NEBD 
 
z
 
10–20 min after microinjection (8/8
cells). Thus, microinjecting p21N mimicked the effect of
the prophase checkpoint.
 
p21N Cannot Prevent Cells from Completing Mitosis 
after Cyclin B1/CDK1 Has Translocated into
the Nucleus
 
From our studies, and from those of Rieder and Cole
(1998), there appeared to be a point in mid to late pro-
phase after which the cells are committed to NEBD. From
our results, this point correlated with the time when the
nucleoli disappeared. One event that occurs at approxi-
mately this time is the translocation of cyclin B1/CDK1
into the nucleus, therefore, we reasoned that the translo-
cation of cyclin B1/CDK1 might mark the point of no re-
turn for mitosis. We have previously shown that a cyclin
B1-GFP fusion protein acts as a proper marker for the en-
dogenous cyclin B1 (Hagting et al., 1998, 1999). Therefore,
we correlated the behavior of a cyclin B1-GFP chimaera in
PtK
 
1
 
 cells with the morphology of prophase nuclei under
DIC microscopy. We found an excellent agreement be-
tween the time at which the nucleoli disappeared, which
marks the point when p21N is unable to return the cells to
interphase, and the time when cyclin B1-GFP translocated
into the nucleus (Fig. 7).
 
activity with 
 
g
 
-[
 
33
 
P]ATP. GST-p21N was produced and purified from 
 
E
 
.
 
 coli
 
 and added to the cyclin-Cdk incubations at the indicated
concentrations. At a 40-fold excess of p21N, cyclin A/CDK2 is almost completely inhibited but cyclin B1-CDK1 is unaffected. (B) p21N
prevents cells from entering mitosis. G2 phase HeLa cells were injected or not with a final concentration of 2 
 
m
 
M p21N (filled circles,
representing 
 
z
 
40-fold excess over cyclin A/CDK2), or p21N preincubated with cyclin A/CDK2K33R (open diamonds), or with GST
(open squares) and their entry into mitosis followed by time-lapse microscopy. A minimum of 25 cells were followed for each sample.
The results are plotted with zero time set as the time when 50% of the control cells entered mitosis and are representative of at least two
independent experiments. (C) Cells arrested by p21N arrest in G2 phase. G2 phase HeLa cells were injected or not with a final concen-
tration of 2 
 
m
 
M p21N and fixed and stained for immunofluorescence. Cells were stained with anti–cyclin B1 as a marker of G2 phase,
and anti-tubulin to visualize any mitotic spindles. (a) Control cells that have mostly reentered G1 phase; (b) p21N-injected cells fixed at
a time when all the control cells had completed mitosis. 
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Discussion
 
Cyclin A/CDK2 Can Promote Mitosis
 
In this paper we have used time-lapse DIC microscopy to
study the requirement for cyclin A/CDK2 at mitosis. In
our experiments we used cyclin A/CDK2 because this is
the major form of cyclin A/CDK activity in G2 phase in
HeLa cells (Pines and Hunter, 1990).
 
 
 
We have demon-
strated that cyclin A/CDK2 activity appears to be rate lim-
iting for the initiation of mitosis in G2 phase because puri-
fied, active cyclin A/CDK2 kinase will initiate mitosis
within 30 min of microinjection if cells have finished DNA
replication. This role for CDK2 kinase in the initiation of
mitosis is consistent with experiments using 
 
Xenopus
 
 ex-
tracts, where CDK2 was shown to be a positive regulator
of cyclin B/CDK1 (Guadagno and Newport, 1996). How-
ever, in these embryonic extracts CDK2 was partnered
with cyclin E, whereas we found that cyclin E/CDK2 was
unable to promote mitosis. Thus, it appears that the role of
the CDK2 kinase in promoting mitosis is conserved in
adult, mammalian cells but that the cyclin partner has al-
tered to cyclin A. We have also used the amino terminus
of p21 as a specific inhibitor of cyclin A/CDK2 to demon-
strate that cyclin A/CDK2 activity is not only required for
cells to enter mitosis, but also to progress through mitosis
until the middle of prophase. If cyclin A/CDK2 is inhibited
in early or mid prophase this causes the cell to return to in-
terphase. However, cyclin A/CDK2 becomes dispensable
once cyclin B has translocated into the nucleus.
 
Cyclin A/CDK as a Target of the Cell Cycle
Checkpoint Machinery
 
Active cyclin A/CDK2 is able to accelerate entry into mi-
tosis by at least 4 h, effectively eliminating G2 phase.
However, if cyclin A/CDK2 is injected into cells that are
still replicating their DNA, this has no effect on the timing
of mitosis in 
 
.
 
90% of the injected cells. This may be be-
cause the appropriate mitotic substrates are not present,
or are inaccessible, in S phase cells. Alternatively, S phase
cells may be able to inactivate the mitosis-promoting activ-
ity of excess cyclin A/CDK2. Thus, in addition to the inhi-
bition of Cdc25 by Cds1 and Chk1 (Boddy et al., 1998), the
negative regulation of cyclin A/CDK2 may underlie the
observation that S phase nuclei are able to delay the entry
of G2 cells into mitosis (Rao and Johnson, 1970). We have
 
Figure 5.
 
Activators of cyclin B-CDK2 and active cyclin B-CDK2
itself overcome the p21 block. (A) G2 phase HeLa cells were mi-
croinjected or not at the indicated time with p21 to a final con-
centration of 2–4 
 
m
 
M, and the cDNA encoding cdc25B3 under
the CMV promoter at a concentration of 0.1
 
m
 
g/
 
m
 
l. Entry into mi-
tosis was followed by time-lapse microscopy and a minimum of
21 cells were followed for each sample. The results are plotted
with zero time set as the time when 50% of the control cells en-
tered mitosis and are representative of at least two independent
experiments. (B) G2 phase HeLa cells were microinjected or not
 
at the indicated time with p21N to a final concentration of 2–4 
 
m
 
M,
and the cDNA encoding cdc25C under the CMV promoter at a
concentration of 0.1 
 
m
 
g/
 
m
 
l. Entry into mitosis was followed by
time-lapse microscopy and a minimum of 23 cells were followed
for each sample. The results are plotted with zero time set as the
time when 50% of the control cells entered mitosis and are repre-
sentative of at least two independent experiments. (C) G2 phase
HeLa cells were microinjected or not at the indicated time with
p21N to a final concentration of 2–4 
 
m
 
M, and purified active cy-
clin B1-CDK1 (
 
z
 
2 
 
m
 
M). Entry into mitosis was followed by time-
lapse microscopy and a minimum of 20 cells was followed for
each sample. The results are plotted with zero time set as the
time when 50% of the control cells entered mitosis and are repre-
sentative of at least two independent experiments. 
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shown that any inactivation is not through degrading cy-
clin A, therefore, it could be through cyclin A/CDK being
bound by an excess of CDK inhibitors such as p21
 
Cip1
 
, or
p27
 
Kip1
 
 or p57
 
Kip2
 
. However, recent results have shown
that there is little free p21
 
Cip1
 
 after S phase begins (Cai
and Dynlacht, 1998) and p27Kip1 levels fall substantially
through ubiquitin-dependent proteolysis in late G1 phase
(Pagano et al., 1995). By analogy with the inactivation of
cyclin B-CDK1 after DNA damage, cyclin A/CDK2 might
be inactivated by phosphorylating CDK2 on threonine 14
(T14) and/or tyrosine 15 (Y15). Interestingly, when we mi-
croinjected cyclin A/CDK2 into cells that were arrested in
G2 phase by UV irradiation, we found that the cells
rounded up but then flattened out again without breaking
down their nuclear envelopes (data not shown). Our inter-
pretation of this is that cyclin A/CDK2 was not inacti-
vated, but it could not drive cells further than prophase be-
cause cyclin B1/CDK1 was inhibited by the UV treatment.
Our results may be relevant to the observations of Bunz
et al. (1998), who showed that in addition to phosphorylat-
ing and inactivating cyclin B/CDK1, cells require p21Cip1 to
maintain a G2 arrest after DNA damage. We would sug-
gest that p21Cip1 is required to inhibit the M-phase–pro-
moting activity of cyclin A/CDK in G2 phase. Interest-
ingly, when the p53 target gene GADD45 is overexpressed
in primary human fibroblasts, they arrest as rounded up
cells with condensed DNA and stain strongly for MPM-2
epitopes, but still have intact nuclear envelopes (Wang et al.,
1999). This arrest point corresponds to that of cells with
active cyclin A/CDK2 but inactive cyclin B1/CDK1. Thus,
GADD45 appears to inhibit the step(s) between the initia-
tion of prophase by cyclin A/CDK, and the activation of
cyclin B1/CDK1 to initiate nuclear envelope breakdown.
Indeed, GADD45 has been shown to bind and inactivate
cyclin B/CDK complexes (Zhan et al., 1999).
In most cases, we observed that the early entry into mi-
tosis promoted by excess cyclin A/CDK2 was accompa-
nied by a delayed metaphase, but eventually the cells did
divide properly and remained separate. In other cases,
mostly in early G2 phase cells and in the small minority of
S phase cells that could be forced into mitosis by cyclin
A/CDK2, the chromosomes never fully condensed, proba-
bly because DNA replication was not complete. These
cells had a prolonged mitosis and the daughter cells fused
after division. The cell fusion may have been caused by in-
completely replicated chromosomes, leading to the pres-
ence of chromatin in the region of the cytokinetic furrow,
which has been shown to cause the furrow to regress and
the daughter cells to fuse (Mullins and Biesele, 1977).
Cyclin A/CDK2 Acts Upstream of Cyclin B/CDK1
Cyclin A/CDK2 appears to act upstream of cyclin B1/
CDK1 activation. We were able to block the mitosis-pro-
moting effects of cyclin A/CDK2 by expressing a phos-
phatase-inactive mutant of Cdc25B or, less effectively, by
a catalytically inactive form of Cdc25C. (The partial block
by the phosphatase-dead form of Cdc25C is likely to be
because it is less effective at competing against the pool
of the endogenous protein compared with the mutant
Cdc25B, given that Cdc25C is a more stable protein than
Cdc25B.) The dominant negative Cdc25s blocked cells in
prophase, before nuclear envelope breakdown. Consistent
with these results, overexpressing either form of Cdc25, or
injecting active cyclin B1/CDK1, was able to overcome the
block to mitosis imposed by inhibiting cyclin A/CDK2
with p21N. These results suggest that cyclin A/CDK activ-
ity is able to drive cells through most of prophase, but that
cyclin B/CDK activity is required at the end of prophase
for nuclear envelope breakdown.
Our experiments have revealed that cyclin A/CDK ac-
tivity, rather than cyclin B1/CDK1 activity, is likely to be
responsible, directly or indirectly, for a number of changes
in the cell as it enters mitosis. Cells that return to inter-
phase when cyclin A/CDK is inactivated by p21N have al-
ready begun to condense their chromosomes, to disassem-
ble their nucleoli and to round up. Rieder and Cole (1998)
showed that a number of mitosis-specific MPM-2 antigens
and phosphorylated histone H3 are also present in cells at
this point in mitosis. However, once cyclin B1/CDK1 has
Figure 6. p21N will cause a
prophase cell to return to G2
phase. PtK1 cells in prophase
were microinjected with purified
GST-p21N to a final concentra-
tion of 2–4 mM and visualized by
time-lapse DIC microscopy. (A)
PtK1 cells just before microinjec-
tion at 13.20. The condensed
chromosomes are clearly visible.
(B) The same PtK1 cell 115 min
after injection of p21N. The
chromosomes have decondensed
and the nucleolus has reformed.
Images are representative of 17
cells in at least five independent
experiments.The Journal of Cell Biology, Volume 147, 1999 304
translocated into the nucleus, inhibiting cyclin A cannot
force cells back into interphase, and very soon after this
(z10 min later) the cells undergo NEBD. Moreover,
NEBD marks the point at which cyclin A begins to be de-
graded (den Elzen, N., and J. Pines, manuscript in prepa-
ration). Thus, we can view the entry into (mammalian) mi-
tosis as a two stage event; cyclin A–associated kinase is
required for cells to progress into and through prophase,
i.e., to condense chromosomes, for the disassembly of the
nucleoli, and for the activation and or translocation of cy-
clin B/CDK1. Once cyclin B1/CDK1 has been activated
it is required for progress into metaphase, i.e., for com-
pleting chromosome condensation, for nuclear envelope
breakdown and completing formation of the mitotic spin-
dle. We note that the centrosomes begin to separate just
before cyclin B1 enters the nucleus, making it possible for
either cyclin A or cyclin B1 to initiate centrosome separa-
tion, although our observation that p21N does not block
cells from completing mitosis after the nucleolus disap-
pears suggests that cyclin A/CDK activity is not required
to form the spindle itself. Nevertheless, determining the
precise time at which cyclin B1/CDK1 is activated, i.e., be-
fore or after translocation to the nucleus, is critical for a
proper understanding of the irreversible commitment to
mitosis. In this respect, studies on maturing starfish oo-
cytes have shown that cyclin B-associated histone H1 ki-
nase activity appears z10 min before cyclin B1 enters the
nucleus at meiosis I (Ookata et al., 1992). It will also be in-
teresting to determine whether there is another cyclin,
perhaps a mammalian cyclin B3, that is subsequently re-
quired for some of the events in anaphase and/or telo-
phase.
Cyclin A/CDK May Be the Target of the
Prophase Checkpoint
Our studies also suggest that cyclin A/CDK could be the
target of the DNA damage checkpoint in prophase.
Rieder and Cole (1998) noted that prophase PtK1 cells
would return to interphase if they were damaged .30 min
before NEBD. In our experiments, p21N causes PtK1 cells
to return to mitosis if they were .10–20 min before
Figure 7. Cyclin B1-GFP translocates into the nucleus at the end of prophase just after the nucleolus disappears. PtK1 cells in late G2
phase were injected with purified cyclin B1-GFP. Cells were imaged by time-lapse fluorescence and DIC microscopy and images cap-
tured at the indicated times. DIC and fluorescence images show that cyclin B1-GFP translocates into the nucleus just after the nucleolus
disappears between the 80 and 100 time points (the nucleolus is indicated by an arrow). Images are representative of two independent
experiments in this study, and confirmed by several other studies in this laboratory (Hagting et al., 1999).Furuno et al. Cyclin A Is Required for Prophase 305
NEBD. The difference in timing may reflect the time
needed to transduce the signal from damaged DNA in
Rieder and Cole’s studies, compared with our experiments
in which we directly introduce an effector molecule.
Should a CKI inhibitor be the natural effector molecule
we would predict that p21Cip12/2 (or p21Cip12/2/p27Kip12/2)
cells will have a defective prophase checkpoint.
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